Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  MUMBAI STOCK EXCHANGE  >  Dr. Reddy's Laboratories Limited    500124   INE089A01023

DR. REDDY'S LABORATORIES LIMITED

(500124)
  Report
End-of-day quote. End-of-day quote MUMBAI STOCK EXCHANGE - 10/27
5100.3 INR   +2.41%
04:35aDR REDDY LABORATORIES : 2Q Net Fell 30%
DJ
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22DR REDDY LABORATORIES : Data breach prompts India's Dr Reddy's to shut key plants - ET Now
RE
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsPress ReleasesOfficial PublicationsSector news

Serum Institute, Bharat Biotech to begin trial of intranasal COVID-19 vaccine soon: Vardhan

share with twitter share with LinkedIn share with facebook
10/18/2020 | 01:03pm EDT
FILE PHOTO: Small bottles labeled with a

NEW DELHI (Reuters) - Serum Institute of India and Bharat Biotech are expected to pursue late stage clinical trials of intranasal COVID-19 vaccines in the coming months once they receive regulatory approval, Health Minister Dr Harsh Vardhan said on Sunday.

Vardhan said the late stage trial generally involves thousands of participants, sometimes 30,000 to 40,000.

Of the vaccines currently in Phase 3 trials, all are administered by injection, according to the World Health Organization (WHO).

On Saturday, India's Dr Reddy's Laboratories Ltd and the Russian Direct Investment Fund (RDIF) said they have received renewed approval to conduct late-stage clinical trials in India of the Russian COVID-19 vaccine.

India's coronavirus infections rose by another 61,871 over the past 24 hours, data released on Sunday showed, although the health ministry said it is seeing a trend of steadily declining active cases.

The Indian Council of Medical Research (ICMR) said it will revisit its protocol for COVID-19 treatment after the WHO found some of the commonly used drugs, including remdesivir, had little or no impact on a patient's chances of surviving, local media reported earlier on Sunday.

(Reporting by Aditi Shah; Editing by Alexandra Hudson)


share with twitter share with LinkedIn share with facebook
All news about DR. REDDY'S LABORATORIES LIMITED
04:35aDR REDDY LABORATORIES : 2Q Net Fell 30%
DJ
10/22Dr Reddy's isolates data center services after cyberattack
RE
10/22DR REDDY LABORATORIES : Data breach prompts India's Dr Reddy's to shut key plant..
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/22Fujifilm partners Shanghai firm to seek China COVID-19 approval for Avigan
RE
10/21DR REDDY LABORATORIES : . Reddy's announces the re-launch of over-the-counter Fa..
AQ
10/20DR REDDY LABORATORIES : . Reddy's announces the re-launch of over-the-counter Fa..
BU
10/19Fujifilm seeks approval for Avigan as COVID-19 treatment in Japan
RE
10/18SERUM INSTITUTE, BHARAT BIOTECH TO B : Vardhan
RE
10/17DR REDDY LABORATORIES : . Reddy's and RDIF receive approval to conduct clinical ..
BU
More news
Financials
Sales 2021 191 B 2 592 M 2 592 M
Net income 2021 26 056 M 353 M 353 M
Net cash 2021 8 440 M 114 M 114 M
P/E ratio 2021 32,5x
Yield 2021 0,50%
Capitalization 846 B 11 488 M 11 470 M
EV / Sales 2021 4,38x
EV / Sales 2022 3,82x
Nbr of Employees 21 650
Free-Float 69,0%
Chart DR. REDDY'S LABORATORIES LIMITED
Duration : Period :
Dr. Reddy's Laboratories Limited Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends DR. REDDY'S LABORATORIES LIMITED
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 34
Average target price 5 186,84 INR
Last Close Price 5 100,30 INR
Spread / Highest target 26,5%
Spread / Average Target 1,70%
Spread / Lowest Target -27,5%
EPS Revisions
Managers
NameTitle
Erez Israeli Chief Executive & Operating Officer
Saumen Chakraborty President, CFO & Global Head-IT
Satish Kallam Reddy Co-Chairman
Gunupati Venkateswara Prasad Co-Chairman & Managing Director
Kalpana Jaisingh Morparia Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
DR. REDDY'S LABORATORIES LIMITED77.27%11 488
JOHNSON & JOHNSON-1.86%376 848
ROCHE HOLDING AG-4.22%283 828
PFIZER INC.-4.47%207 994
MERCK & CO., INC.-14.25%197 256
NOVARTIS AG-19.31%180 257